 Michael Mitchell
Concepts (780)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nanoparticles | 104 | 2026 | 512 | 37.000 |
Why?
| | Lipids | 63 | 2026 | 706 | 22.810 |
Why?
| | RNA, Messenger | 57 | 2026 | 2815 | 16.030 |
Why?
| | Liposomes | 77 | 2026 | 256 | 12.610 |
Why?
| | Drug Delivery Systems | 26 | 2026 | 380 | 7.940 |
Why?
| | Gene Editing | 15 | 2026 | 91 | 6.270 |
Why?
| | Immunotherapy | 16 | 2026 | 662 | 5.080 |
Why?
| | T-Lymphocytes | 18 | 2026 | 1984 | 4.880 |
Why?
| | Gene Transfer Techniques | 11 | 2026 | 186 | 3.980 |
Why?
| | Mice | 113 | 2026 | 18261 | 3.920 |
Why?
| | Neoplasms | 22 | 2026 | 2873 | 3.870 |
Why?
| | Animals | 150 | 2026 | 37948 | 3.570 |
Why?
| | Infertility, Male | 12 | 2026 | 74 | 3.310 |
Why?
| | RNA, Small Interfering | 22 | 2026 | 631 | 3.140 |
Why?
| | Y Chromosome | 29 | 2016 | 36 | 3.020 |
Why?
| | Placenta | 8 | 2025 | 781 | 2.960 |
Why?
| | CRISPR-Cas Systems | 6 | 2025 | 167 | 2.810 |
Why?
| | Neoplastic Cells, Circulating | 9 | 2015 | 80 | 2.730 |
Why?
| | High-Throughput Screening Assays | 4 | 2026 | 176 | 2.600 |
Why?
| | Cancer Vaccines | 6 | 2026 | 160 | 2.550 |
Why?
| | Autoimmune Diseases | 4 | 2025 | 465 | 2.510 |
Why?
| | Spermatogenesis | 20 | 2026 | 91 | 2.480 |
Why?
| | Cell Engineering | 6 | 2026 | 14 | 2.410 |
Why?
| | Immunotherapy, Adoptive | 6 | 2026 | 339 | 2.370 |
Why?
| | Spermatozoa | 9 | 2026 | 107 | 2.270 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 6 | 2024 | 54 | 2.010 |
Why?
| | Transfection | 12 | 2026 | 924 | 1.950 |
Why?
| | Humans | 174 | 2026 | 144667 | 1.910 |
Why?
| | Cell Line, Tumor | 22 | 2026 | 3523 | 1.890 |
Why?
| | Chromosomes, Human, Y | 10 | 2012 | 37 | 1.750 |
Why?
| | Endosomes | 3 | 2025 | 140 | 1.730 |
Why?
| | Nanomedicine | 6 | 2025 | 46 | 1.680 |
Why?
| | Ribonucleoproteins | 2 | 2025 | 104 | 1.620 |
Why?
| | Antibodies, Bispecific | 2 | 2025 | 69 | 1.610 |
Why?
| | Antineoplastic Agents | 6 | 2026 | 2201 | 1.600 |
Why?
| | Nanostructures | 5 | 2024 | 110 | 1.590 |
Why?
| | Nucleic Acids | 2 | 2025 | 72 | 1.580 |
Why?
| | Mice, Inbred C57BL | 24 | 2026 | 5967 | 1.540 |
Why?
| | DNA-Binding Proteins | 11 | 2026 | 1484 | 1.480 |
Why?
| | Leukocytes | 7 | 2023 | 294 | 1.450 |
Why?
| | Liver | 7 | 2026 | 1889 | 1.430 |
Why?
| | Microfluidics | 5 | 2025 | 62 | 1.410 |
Why?
| | Blood-Brain Barrier | 5 | 2026 | 155 | 1.360 |
Why?
| | Genetic Therapy | 6 | 2024 | 313 | 1.350 |
Why?
| | Nuclear Proteins | 11 | 2026 | 741 | 1.300 |
Why?
| | Tumor Microenvironment | 10 | 2026 | 729 | 1.300 |
Why?
| | Spleen | 2 | 2025 | 510 | 1.300 |
Why?
| | Peptides | 4 | 2025 | 989 | 1.290 |
Why?
| | Vaccines | 3 | 2026 | 388 | 1.280 |
Why?
| | Oligospermia | 5 | 2016 | 13 | 1.260 |
Why?
| | Drug Carriers | 5 | 2026 | 132 | 1.250 |
Why?
| | Cyclodextrins | 2 | 2020 | 11 | 1.210 |
Why?
| | RNA | 4 | 2026 | 926 | 1.200 |
Why?
| | Biomedical Engineering | 2 | 2020 | 30 | 1.180 |
Why?
| | Brain | 6 | 2026 | 2934 | 1.160 |
Why?
| | Spermatids | 4 | 2026 | 25 | 1.160 |
Why?
| | Azoospermia | 5 | 2017 | 10 | 1.130 |
Why?
| | Nuclear Pore Complex Proteins | 2 | 2026 | 40 | 1.130 |
Why?
| | Lab-On-A-Chip Devices | 4 | 2025 | 60 | 1.120 |
Why?
| | Stress, Mechanical | 7 | 2017 | 494 | 1.070 |
Why?
| | Transcription Factors | 11 | 2016 | 1726 | 1.040 |
Why?
| | Dendrimers | 2 | 2025 | 21 | 1.040 |
Why?
| | Antigen-Presenting Cells | 2 | 2026 | 159 | 1.020 |
Why?
| | Diphosphonates | 2 | 2024 | 68 | 1.010 |
Why?
| | DNA | 9 | 2024 | 1447 | 1.010 |
Why?
| | Sperm Head | 2 | 2017 | 5 | 1.000 |
Why?
| | Surface-Active Agents | 3 | 2021 | 99 | 0.990 |
Why?
| | E-Selectin | 4 | 2015 | 61 | 0.990 |
Why?
| | Colonic Neoplasms | 2 | 2026 | 256 | 0.970 |
Why?
| | Mouth Neoplasms | 1 | 2026 | 90 | 0.910 |
Why?
| | Prodrugs | 1 | 2026 | 52 | 0.910 |
Why?
| | Extracellular Vesicles | 2 | 2026 | 171 | 0.900 |
Why?
| | Exosomes | 2 | 2023 | 104 | 0.890 |
Why?
| | Nanotubes | 3 | 2015 | 46 | 0.890 |
Why?
| | Lymph Nodes | 2 | 2026 | 501 | 0.880 |
Why?
| | Membrane Proteins | 5 | 2026 | 1159 | 0.870 |
Why?
| | Bone Marrow | 2 | 2023 | 306 | 0.860 |
Why?
| | Siloxanes | 1 | 2024 | 7 | 0.860 |
Why?
| | Biocompatible Materials | 3 | 2019 | 436 | 0.860 |
Why?
| | HIV | 1 | 2026 | 248 | 0.860 |
Why?
| | Endothelial Cells | 9 | 2024 | 864 | 0.850 |
Why?
| | Amidines | 1 | 2024 | 15 | 0.850 |
Why?
| | Pyridones | 1 | 2026 | 201 | 0.850 |
Why?
| | Cations | 1 | 2024 | 82 | 0.840 |
Why?
| | Apoptosis | 9 | 2024 | 2397 | 0.830 |
Why?
| | Amantadine | 1 | 2024 | 8 | 0.830 |
Why?
| | Skin Diseases | 1 | 2026 | 151 | 0.820 |
Why?
| | Oncolytic Viruses | 1 | 2024 | 8 | 0.820 |
Why?
| | Oncolytic Virotherapy | 1 | 2024 | 13 | 0.820 |
Why?
| | Female | 66 | 2026 | 78304 | 0.820 |
Why?
| | Genital Neoplasms, Female | 1 | 2025 | 99 | 0.810 |
Why?
| | CD3 Complex | 1 | 2024 | 111 | 0.800 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2024 | 550 | 0.790 |
Why?
| | Polymers | 5 | 2026 | 492 | 0.790 |
Why?
| | Antigens, Neoplasm | 3 | 2026 | 272 | 0.790 |
Why?
| | X Chromosome | 13 | 2016 | 65 | 0.780 |
Why?
| | Placenta Diseases | 1 | 2023 | 19 | 0.780 |
Why?
| | Cystic Fibrosis | 2 | 2025 | 1166 | 0.780 |
Why?
| | Neurotoxicity Syndromes | 1 | 2023 | 40 | 0.770 |
Why?
| | Microtubules | 1 | 2026 | 287 | 0.770 |
Why?
| | Neutrophil Activation | 2 | 2014 | 84 | 0.750 |
Why?
| | Hypersensitivity | 1 | 2025 | 253 | 0.750 |
Why?
| | Wnt Proteins | 2 | 2026 | 133 | 0.750 |
Why?
| | Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2023 | 80 | 0.740 |
Why?
| | Killer Cells, Natural | 3 | 2025 | 470 | 0.740 |
Why?
| | Bile Acids and Salts | 1 | 2024 | 163 | 0.740 |
Why?
| | Spermatocytes | 7 | 2014 | 18 | 0.730 |
Why?
| | Lung | 7 | 2025 | 4089 | 0.730 |
Why?
| | Pre-Eclampsia | 1 | 2024 | 203 | 0.730 |
Why?
| | Mesothelioma | 1 | 2022 | 50 | 0.720 |
Why?
| | Dendritic Cells | 5 | 2026 | 498 | 0.720 |
Why?
| | Bone and Bones | 1 | 2024 | 317 | 0.710 |
Why?
| | Precision Medicine | 3 | 2020 | 454 | 0.700 |
Why?
| | Trophoblasts | 4 | 2025 | 218 | 0.700 |
Why?
| | Antioxidants | 1 | 2025 | 546 | 0.690 |
Why?
| | Pregnancy | 10 | 2025 | 7122 | 0.690 |
Why?
| | Wnt Signaling Pathway | 2 | 2026 | 210 | 0.690 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2025 | 371 | 0.690 |
Why?
| | Placental Insufficiency | 1 | 2023 | 126 | 0.680 |
Why?
| | Polyethylene Glycols | 5 | 2026 | 652 | 0.680 |
Why?
| | Fatty Acids | 1 | 2024 | 454 | 0.670 |
Why?
| | Amniotic Fluid | 1 | 2021 | 79 | 0.670 |
Why?
| | Shear Strength | 4 | 2015 | 73 | 0.670 |
Why?
| | Testis | 6 | 2023 | 162 | 0.670 |
Why?
| | Meiosis | 10 | 2015 | 101 | 0.660 |
Why?
| | ErbB Receptors | 1 | 2024 | 632 | 0.660 |
Why?
| | Skin | 1 | 2026 | 762 | 0.650 |
Why?
| | Chromosome Mapping | 16 | 2001 | 507 | 0.650 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2023 | 394 | 0.650 |
Why?
| | Polyneuropathies | 1 | 2021 | 57 | 0.650 |
Why?
| | Sperm Tail | 3 | 2018 | 8 | 0.650 |
Why?
| | Exons | 6 | 2017 | 362 | 0.640 |
Why?
| | Flow Cytometry | 1 | 2024 | 1154 | 0.640 |
Why?
| | Microfluidic Analytical Techniques | 3 | 2025 | 79 | 0.640 |
Why?
| | Biomimetic Materials | 2 | 2026 | 78 | 0.630 |
Why?
| | Fetal Therapies | 1 | 2020 | 47 | 0.620 |
Why?
| | Mutation | 6 | 2018 | 4081 | 0.620 |
Why?
| | Gene Deletion | 7 | 2017 | 392 | 0.610 |
Why?
| | Structure-Activity Relationship | 3 | 2026 | 564 | 0.600 |
Why?
| | Multiple Myeloma | 1 | 2023 | 306 | 0.600 |
Why?
| | Cell Proliferation | 3 | 2026 | 2489 | 0.600 |
Why?
| | Sperm Motility | 2 | 2018 | 35 | 0.590 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 170 | 0.570 |
Why?
| | Calmodulin-Binding Proteins | 1 | 2018 | 14 | 0.570 |
Why?
| | Fetal Diseases | 1 | 2020 | 193 | 0.560 |
Why?
| | Histones | 2 | 2023 | 663 | 0.560 |
Why?
| | Factor IX | 3 | 2015 | 49 | 0.550 |
Why?
| | Calmodulin | 1 | 2018 | 69 | 0.550 |
Why?
| | Proteins | 7 | 2023 | 1016 | 0.540 |
Why?
| | Neoplasm Metastasis | 4 | 2015 | 691 | 0.540 |
Why?
| | Natural Science Disciplines | 1 | 2017 | 2 | 0.540 |
Why?
| | Hemophilia B | 3 | 2015 | 65 | 0.530 |
Why?
| | Pyrazines | 1 | 2018 | 92 | 0.530 |
Why?
| | Cholesterol | 3 | 2025 | 404 | 0.520 |
Why?
| | Tissue Distribution | 5 | 2026 | 335 | 0.510 |
Why?
| | Sequence Deletion | 7 | 2017 | 191 | 0.480 |
Why?
| | Lamin Type A | 2 | 2015 | 50 | 0.480 |
Why?
| | Hydrogels | 1 | 2023 | 703 | 0.470 |
Why?
| | Aluminum Silicates | 2 | 2015 | 17 | 0.470 |
Why?
| | Base Sequence | 18 | 2012 | 2177 | 0.460 |
Why?
| | Male | 64 | 2026 | 72431 | 0.460 |
Why?
| | Selectins | 1 | 2015 | 8 | 0.450 |
Why?
| | Gene Duplication | 1 | 2015 | 67 | 0.440 |
Why?
| | Antibodies, Neoplasm | 1 | 2015 | 34 | 0.440 |
Why?
| | Protein Corona | 2 | 2026 | 6 | 0.440 |
Why?
| | Coated Materials, Biocompatible | 1 | 2015 | 65 | 0.430 |
Why?
| | Molecular Sequence Data | 21 | 2012 | 2909 | 0.430 |
Why?
| | Medical Oncology | 1 | 2017 | 331 | 0.420 |
Why?
| | Pyridines | 2 | 2018 | 603 | 0.420 |
Why?
| | Platelet Activating Factor | 1 | 2014 | 45 | 0.420 |
Why?
| | Mutation, Missense | 4 | 2017 | 338 | 0.420 |
Why?
| | Ligases | 4 | 2000 | 38 | 0.410 |
Why?
| | Excipients | 2 | 2024 | 55 | 0.410 |
Why?
| | Cell Adhesion Molecules | 1 | 2015 | 178 | 0.410 |
Why?
| | Kruppel-Like Transcription Factors | 3 | 2014 | 77 | 0.400 |
Why?
| | Chemical Phenomena | 1 | 2013 | 81 | 0.400 |
Why?
| | Autoimmunity | 3 | 2024 | 930 | 0.400 |
Why?
| | Glycocalyx | 1 | 2013 | 30 | 0.400 |
Why?
| | Cell Adhesion | 4 | 2015 | 452 | 0.380 |
Why?
| | Cell- and Tissue-Based Therapy | 2 | 2025 | 78 | 0.380 |
Why?
| | Adjuvants, Immunologic | 2 | 2025 | 245 | 0.370 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 601 | 0.370 |
Why?
| | Hematopoietic Stem Cells | 3 | 2024 | 419 | 0.370 |
Why?
| | Health Services Accessibility | 1 | 2021 | 1098 | 0.370 |
Why?
| | Phospholipids | 2 | 2025 | 214 | 0.370 |
Why?
| | Factor V | 2 | 2019 | 26 | 0.370 |
Why?
| | Receptors, Formyl Peptide | 1 | 2012 | 17 | 0.360 |
Why?
| | Inverted Repeat Sequences | 1 | 2011 | 18 | 0.360 |
Why?
| | Mitochondria | 1 | 2018 | 984 | 0.340 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2012 | 139 | 0.330 |
Why?
| | Neutrophils | 4 | 2023 | 1118 | 0.330 |
Why?
| | Factor V Deficiency | 1 | 2010 | 2 | 0.330 |
Why?
| | Transcriptional Activation | 2 | 2014 | 372 | 0.330 |
Why?
| | Factor VIII | 3 | 2007 | 105 | 0.330 |
Why?
| | RNA-Binding Proteins | 4 | 2005 | 461 | 0.320 |
Why?
| | Mice, Nude | 2 | 2024 | 677 | 0.310 |
Why?
| | Point Mutation | 2 | 2008 | 242 | 0.300 |
Why?
| | Ligands | 3 | 2024 | 662 | 0.300 |
Why?
| | Amino Acid Substitution | 2 | 2008 | 303 | 0.300 |
Why?
| | Emigration and Immigration | 1 | 2010 | 66 | 0.300 |
Why?
| | Doxorubicin | 1 | 2012 | 398 | 0.300 |
Why?
| | Mice, Knockout | 5 | 2026 | 3109 | 0.300 |
Why?
| | L-Selectin | 3 | 2014 | 27 | 0.300 |
Why?
| | Chromosome Deletion | 3 | 2011 | 124 | 0.300 |
Why?
| | Pseudogenes | 2 | 2000 | 20 | 0.290 |
Why?
| | DNA, Mitochondrial | 1 | 2010 | 212 | 0.290 |
Why?
| | Hemodynamics | 1 | 2014 | 1113 | 0.290 |
Why?
| | Transcription, Genetic | 4 | 2012 | 1468 | 0.280 |
Why?
| | Protamines | 1 | 2008 | 8 | 0.280 |
Why?
| | Nuclear Lamina | 3 | 2017 | 12 | 0.270 |
Why?
| | Cardiac Tamponade | 1 | 2007 | 14 | 0.270 |
Why?
| | Hemophilia A | 3 | 2007 | 147 | 0.260 |
Why?
| | Social Class | 1 | 2009 | 265 | 0.260 |
Why?
| | Factor XI Deficiency | 1 | 2007 | 3 | 0.260 |
Why?
| | Factor XI | 1 | 2007 | 11 | 0.260 |
Why?
| | Chromosomes, Human, X | 2 | 2007 | 76 | 0.260 |
Why?
| | Genetic Variation | 2 | 2010 | 985 | 0.260 |
Why?
| | Prescription Drugs | 2 | 2020 | 109 | 0.250 |
Why?
| | Biopsy, Needle | 1 | 2007 | 184 | 0.250 |
Why?
| | Endothelium, Vascular | 1 | 2013 | 949 | 0.250 |
Why?
| | Transgenes | 3 | 2026 | 191 | 0.250 |
Why?
| | Lung Neoplasms | 2 | 2018 | 2660 | 0.240 |
Why?
| | Recombination, Genetic | 5 | 2015 | 205 | 0.240 |
Why?
| | Pedigree | 5 | 2017 | 515 | 0.240 |
Why?
| | Nanodiamonds | 1 | 2026 | 1 | 0.240 |
Why?
| | Radiography, Interventional | 1 | 2007 | 128 | 0.240 |
Why?
| | Inflammation | 4 | 2025 | 2870 | 0.240 |
Why?
| | Nuclear Pore | 1 | 2026 | 18 | 0.240 |
Why?
| | Homozygote | 3 | 2017 | 200 | 0.240 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 6 | 2017 | 973 | 0.230 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2026 | 48 | 0.230 |
Why?
| | Sex-Determining Region Y Protein | 5 | 2016 | 7 | 0.230 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2009 | 337 | 0.230 |
Why?
| | Receptor, Adenosine A2A | 1 | 2025 | 23 | 0.230 |
Why?
| | DNA Primers | 9 | 2011 | 507 | 0.230 |
Why?
| | Interleukin-12 | 1 | 2026 | 117 | 0.230 |
Why?
| | Combinatorial Chemistry Techniques | 1 | 2025 | 17 | 0.230 |
Why?
| | Nuclear Envelope | 1 | 2026 | 46 | 0.230 |
Why?
| | Immune Tolerance | 2 | 2025 | 381 | 0.220 |
Why?
| | Receptors, Notch | 1 | 2026 | 90 | 0.220 |
Why?
| | Interferon Type I | 1 | 2026 | 146 | 0.220 |
Why?
| | Blood Coagulation | 1 | 2007 | 268 | 0.220 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2025 | 68 | 0.220 |
Why?
| | Heart Arrest | 1 | 2009 | 406 | 0.220 |
Why?
| | Antigen Presentation | 1 | 2026 | 206 | 0.220 |
Why?
| | Transglutaminases | 1 | 2026 | 159 | 0.220 |
Why?
| | Macrophages | 4 | 2025 | 1496 | 0.220 |
Why?
| | Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2025 | 35 | 0.220 |
Why?
| | Lubricants | 1 | 2024 | 3 | 0.220 |
Why?
| | Lipoproteins | 1 | 2026 | 165 | 0.220 |
Why?
| | Biofouling | 1 | 2024 | 8 | 0.220 |
Why?
| | Silver Compounds | 1 | 2024 | 5 | 0.220 |
Why?
| | Interleukin-4 | 1 | 2025 | 206 | 0.220 |
Why?
| | Leukocytes, Mononuclear | 3 | 2023 | 572 | 0.220 |
Why?
| | MCF-7 Cells | 2 | 2015 | 132 | 0.220 |
Why?
| | rab27 GTP-Binding Proteins | 1 | 2024 | 1 | 0.220 |
Why?
| | Biological Evolution | 4 | 2010 | 488 | 0.220 |
Why?
| | Durapatite | 1 | 2024 | 37 | 0.210 |
Why?
| | Sarcoma, Ewing | 1 | 2025 | 103 | 0.210 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2024 | 74 | 0.210 |
Why?
| | Elasticity | 1 | 2025 | 188 | 0.210 |
Why?
| | DNA, B-Form | 1 | 2024 | 2 | 0.210 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2025 | 130 | 0.210 |
Why?
| | Gonadoblastoma | 1 | 2004 | 7 | 0.210 |
Why?
| | Cholic Acids | 1 | 2024 | 13 | 0.210 |
Why?
| | Antibodies, Viral | 2 | 2025 | 672 | 0.210 |
Why?
| | In Situ Hybridization, Fluorescence | 6 | 2012 | 323 | 0.210 |
Why?
| | Injections, Intravenous | 1 | 2024 | 198 | 0.200 |
Why?
| | Eukaryotic Initiation Factor-2 | 4 | 2016 | 33 | 0.200 |
Why?
| | Lipid Bilayers | 2 | 2022 | 101 | 0.200 |
Why?
| | Cellular Microenvironment | 1 | 2024 | 93 | 0.200 |
Why?
| | Vaccines, DNA | 1 | 2024 | 32 | 0.200 |
Why?
| | Myocardial Contraction | 1 | 2025 | 288 | 0.200 |
Why?
| | Semen | 1 | 2023 | 24 | 0.200 |
Why?
| | Injections, Intramuscular | 1 | 2024 | 144 | 0.200 |
Why?
| | Genome | 3 | 2002 | 305 | 0.200 |
Why?
| | Proteolysis | 1 | 2024 | 170 | 0.200 |
Why?
| | Plant Immunity | 1 | 2023 | 4 | 0.200 |
Why?
| | Macrophage-1 Antigen | 2 | 2014 | 26 | 0.200 |
Why?
| | Cyclophilin A | 1 | 2023 | 27 | 0.200 |
Why?
| | Cell Separation | 2 | 2015 | 303 | 0.190 |
Why?
| | Peritoneal Fibrosis | 1 | 2023 | 2 | 0.190 |
Why?
| | ras Proteins | 1 | 2024 | 151 | 0.190 |
Why?
| | Macrophage Activation | 1 | 2024 | 186 | 0.190 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 254 | 0.190 |
Why?
| | Biomarkers, Tumor | 2 | 2015 | 1319 | 0.190 |
Why?
| | Promoter Regions, Genetic | 1 | 2007 | 1246 | 0.190 |
Why?
| | Neoplasm Proteins | 2 | 2017 | 441 | 0.190 |
Why?
| | Pesticides | 1 | 2023 | 63 | 0.190 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2023 | 103 | 0.190 |
Why?
| | Immune System | 1 | 2024 | 178 | 0.190 |
Why?
| | Forkhead Transcription Factors | 1 | 2023 | 203 | 0.190 |
Why?
| | Influenza, Human | 2 | 2024 | 618 | 0.190 |
Why?
| | Cell Nucleus | 1 | 2026 | 592 | 0.180 |
Why?
| | Hydroxycholesterols | 1 | 2022 | 5 | 0.180 |
Why?
| | Chromosome Pairing | 3 | 2011 | 11 | 0.180 |
Why?
| | Sequence Homology, Nucleic Acid | 3 | 2012 | 156 | 0.180 |
Why?
| | Reactive Oxygen Species | 1 | 2025 | 601 | 0.180 |
Why?
| | Zika Virus | 1 | 2023 | 135 | 0.180 |
Why?
| | Heterozygote | 4 | 2017 | 313 | 0.180 |
Why?
| | Emergency Medical Services | 1 | 2009 | 695 | 0.180 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2026 | 294 | 0.180 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2026 | 532 | 0.180 |
Why?
| | Reproductive Health | 1 | 2023 | 90 | 0.180 |
Why?
| | H-Y Antigen | 4 | 2000 | 10 | 0.180 |
Why?
| | Brain Diseases | 1 | 2023 | 152 | 0.180 |
Why?
| | Pneumonia, Viral | 2 | 2024 | 387 | 0.180 |
Why?
| | Phenotype | 7 | 2025 | 3147 | 0.180 |
Why?
| | Lymphocyte Activation | 1 | 2026 | 1124 | 0.180 |
Why?
| | HeLa Cells | 3 | 2018 | 632 | 0.180 |
Why?
| | Ions | 1 | 2021 | 68 | 0.170 |
Why?
| | Calcium-Binding Proteins | 2 | 2024 | 222 | 0.170 |
Why?
| | Thrombosis | 2 | 2023 | 396 | 0.170 |
Why?
| | Surface Properties | 2 | 2024 | 397 | 0.170 |
Why?
| | Myocytes, Cardiac | 2 | 2025 | 538 | 0.170 |
Why?
| | Antibodies | 1 | 2023 | 396 | 0.170 |
Why?
| | Contrast Media | 1 | 2024 | 492 | 0.170 |
Why?
| | Zika Virus Infection | 1 | 2023 | 171 | 0.170 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2017 | 906 | 0.170 |
Why?
| | Interleukin-2 | 1 | 2022 | 438 | 0.170 |
Why?
| | Immunization | 1 | 2023 | 374 | 0.170 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2023 | 264 | 0.170 |
Why?
| | Particle Size | 2 | 2024 | 401 | 0.170 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2026 | 643 | 0.170 |
Why?
| | DNA Mutational Analysis | 5 | 2010 | 409 | 0.170 |
Why?
| | Amino Acid Sequence | 10 | 2011 | 2136 | 0.170 |
Why?
| | Nanospheres | 1 | 2020 | 3 | 0.170 |
Why?
| | Gene Silencing | 2 | 2020 | 202 | 0.160 |
Why?
| | Teratozoospermia | 2 | 2017 | 2 | 0.160 |
Why?
| | Women's Health | 1 | 2023 | 307 | 0.160 |
Why?
| | Alleles | 3 | 2017 | 886 | 0.160 |
Why?
| | Cell Cycle | 1 | 2004 | 595 | 0.160 |
Why?
| | Legislation, Drug | 1 | 2021 | 73 | 0.160 |
Why?
| | Liver Cirrhosis | 1 | 2023 | 287 | 0.160 |
Why?
| | Sex Chromosome Aberrations | 4 | 2007 | 69 | 0.160 |
Why?
| | United States | 8 | 2024 | 16018 | 0.160 |
Why?
| | Adsorption | 1 | 2021 | 152 | 0.160 |
Why?
| | Glioblastoma | 1 | 2024 | 353 | 0.160 |
Why?
| | Stem Cell Niche | 1 | 2020 | 57 | 0.160 |
Why?
| | Myocardium | 1 | 2025 | 928 | 0.160 |
Why?
| | Respiratory Tract Infections | 1 | 2024 | 395 | 0.150 |
Why?
| | Polymerase Chain Reaction | 7 | 2011 | 1047 | 0.150 |
Why?
| | Delayed-Action Preparations | 1 | 2020 | 184 | 0.150 |
Why?
| | Activated Protein C Resistance | 1 | 2019 | 3 | 0.150 |
Why?
| | Reproductive Techniques, Assisted | 2 | 2016 | 43 | 0.150 |
Why?
| | Physician Assistants | 1 | 2021 | 101 | 0.150 |
Why?
| | Bacterial Toxins | 2 | 2012 | 109 | 0.150 |
Why?
| | Coculture Techniques | 1 | 2020 | 245 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 881 | 0.150 |
Why?
| | Nurse Practitioners | 1 | 2021 | 138 | 0.140 |
Why?
| | Swine | 1 | 2021 | 828 | 0.140 |
Why?
| | Drug Prescriptions | 1 | 2021 | 283 | 0.140 |
Why?
| | Blotting, Southern | 6 | 2000 | 84 | 0.140 |
Why?
| | Narcotic Antagonists | 1 | 2021 | 204 | 0.140 |
Why?
| | Sheep | 1 | 2021 | 880 | 0.140 |
Why?
| | Genotype | 5 | 2010 | 1847 | 0.140 |
Why?
| | Antigens | 1 | 2020 | 347 | 0.140 |
Why?
| | Immunosuppressive Agents | 1 | 2023 | 834 | 0.140 |
Why?
| | Axoneme | 1 | 2018 | 10 | 0.140 |
Why?
| | Cell Line | 6 | 2020 | 2821 | 0.140 |
Why?
| | Genetics, Population | 2 | 2010 | 215 | 0.140 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2023 | 496 | 0.140 |
Why?
| | Dyneins | 1 | 2018 | 35 | 0.140 |
Why?
| | Viruses | 1 | 2020 | 166 | 0.140 |
Why?
| | Carcinoma, Renal Cell | 1 | 2021 | 234 | 0.140 |
Why?
| | Cytokines | 2 | 2024 | 2045 | 0.140 |
Why?
| | Disease Models, Animal | 3 | 2024 | 4539 | 0.140 |
Why?
| | Anti-Inflammatory Agents | 1 | 2022 | 477 | 0.140 |
Why?
| | Tetrahymena | 1 | 2018 | 158 | 0.140 |
Why?
| | Recombinant Proteins | 3 | 2024 | 1363 | 0.130 |
Why?
| | Zinc Oxide | 1 | 2017 | 9 | 0.130 |
Why?
| | Health Policy | 1 | 2021 | 398 | 0.130 |
Why?
| | Fetus | 1 | 2022 | 800 | 0.130 |
Why?
| | Serine Peptidase Inhibitors, Kazal Type | 1 | 2017 | 1 | 0.130 |
Why?
| | Asthenozoospermia | 1 | 2017 | 2 | 0.130 |
Why?
| | INDEL Mutation | 1 | 2017 | 20 | 0.130 |
Why?
| | Gene Frequency | 2 | 2017 | 481 | 0.130 |
Why?
| | Nanofibers | 1 | 2017 | 23 | 0.130 |
Why?
| | Pachytene Stage | 2 | 2008 | 2 | 0.130 |
Why?
| | Pancreatic Neoplasms | 1 | 2026 | 926 | 0.130 |
Why?
| | Buprenorphine | 1 | 2021 | 190 | 0.130 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2016 | 221 | 0.130 |
Why?
| | Chromatin | 2 | 2017 | 554 | 0.130 |
Why?
| | Immunity, Innate | 2 | 2022 | 843 | 0.130 |
Why?
| | HT29 Cells | 1 | 2017 | 37 | 0.130 |
Why?
| | Biological Transport | 2 | 2020 | 418 | 0.130 |
Why?
| | Exome | 1 | 2018 | 227 | 0.130 |
Why?
| | Aurora Kinase C | 1 | 2016 | 2 | 0.130 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1268 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 1 | 2007 | 2754 | 0.130 |
Why?
| | Cilia | 1 | 2018 | 173 | 0.120 |
Why?
| | Melanoma | 1 | 2023 | 757 | 0.120 |
Why?
| | Isochromosomes | 1 | 1996 | 2 | 0.120 |
Why?
| | Binding Sites | 2 | 2012 | 1307 | 0.120 |
Why?
| | Kidney Neoplasms | 1 | 2021 | 412 | 0.120 |
Why?
| | Gene Expression Regulation | 4 | 2014 | 2591 | 0.120 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2017 | 195 | 0.120 |
Why?
| | Factor VII Deficiency | 2 | 2007 | 5 | 0.120 |
Why?
| | Biomedical Research | 1 | 2023 | 712 | 0.120 |
Why?
| | Seminiferous Tubules | 1 | 2016 | 13 | 0.120 |
Why?
| | Physical Chromosome Mapping | 1 | 2016 | 20 | 0.120 |
Why?
| | Drug Synergism | 1 | 2017 | 352 | 0.120 |
Why?
| | Genetic Counseling | 1 | 2016 | 81 | 0.120 |
Why?
| | Melanoma, Experimental | 1 | 2016 | 109 | 0.120 |
Why?
| | Pseudoautosomal Regions | 1 | 2015 | 1 | 0.120 |
Why?
| | Mothers | 1 | 2022 | 765 | 0.120 |
Why?
| | Zinc Fingers | 2 | 2012 | 50 | 0.120 |
Why?
| | SOX9 Transcription Factor | 1 | 2016 | 27 | 0.120 |
Why?
| | Bernard-Soulier Syndrome | 1 | 2015 | 1 | 0.120 |
Why?
| | Adult | 13 | 2017 | 40489 | 0.120 |
Why?
| | Ubiquitin-Protein Ligases | 4 | 2000 | 191 | 0.120 |
Why?
| | Sex Chromosomes | 4 | 2011 | 53 | 0.110 |
Why?
| | Neurons | 1 | 2024 | 1639 | 0.110 |
Why?
| | Epithelial Cell Adhesion Molecule | 1 | 2015 | 10 | 0.110 |
Why?
| | Glycoproteins | 1 | 2017 | 353 | 0.110 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2023 | 915 | 0.110 |
Why?
| | Blood Cells | 1 | 2015 | 38 | 0.110 |
Why?
| | Hydrogen-Ion Concentration | 3 | 2026 | 562 | 0.110 |
Why?
| | Cell Survival | 2 | 2019 | 1092 | 0.110 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2015 | 52 | 0.110 |
Why?
| | Tissue Scaffolds | 1 | 2017 | 223 | 0.110 |
Why?
| | Deleted in Azoospermia 1 Protein | 3 | 2005 | 4 | 0.110 |
Why?
| | Lamin Type B | 1 | 2014 | 6 | 0.110 |
Why?
| | Phylogeny | 3 | 2001 | 1024 | 0.110 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2015 | 54 | 0.110 |
Why?
| | Morphogenesis | 1 | 2016 | 172 | 0.110 |
Why?
| | Pregnancy Complications | 1 | 2020 | 586 | 0.110 |
Why?
| | Gene Dosage | 4 | 2016 | 148 | 0.110 |
Why?
| | Conserved Sequence | 2 | 2012 | 247 | 0.110 |
Why?
| | Gene Knockdown Techniques | 1 | 2015 | 334 | 0.110 |
Why?
| | Interphase | 1 | 2014 | 38 | 0.110 |
Why?
| | Rheology | 1 | 2015 | 94 | 0.110 |
Why?
| | Sequence Tagged Sites | 2 | 2011 | 7 | 0.110 |
Why?
| | Receptors, Death Domain | 1 | 2014 | 4 | 0.110 |
Why?
| | Cells, Cultured | 3 | 2020 | 4110 | 0.110 |
Why?
| | Brain Neoplasms | 1 | 2024 | 1327 | 0.100 |
Why?
| | ADAM17 Protein | 1 | 2014 | 42 | 0.100 |
Why?
| | Hemorheology | 1 | 2014 | 24 | 0.100 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2017 | 454 | 0.100 |
Why?
| | Nanotubes, Carbon | 1 | 2014 | 46 | 0.100 |
Why?
| | Taste | 1 | 2016 | 240 | 0.100 |
Why?
| | ADAM Proteins | 1 | 2014 | 64 | 0.100 |
Why?
| | Models, Animal | 1 | 2016 | 393 | 0.100 |
Why?
| | Partial Thromboplastin Time | 2 | 2019 | 52 | 0.100 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 437 | 0.100 |
Why?
| | Metals | 1 | 2014 | 139 | 0.100 |
Why?
| | Serum Albumin | 1 | 2014 | 144 | 0.100 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 265 | 0.100 |
Why?
| | Ubiquitin-Activating Enzymes | 3 | 2000 | 20 | 0.100 |
Why?
| | Laboratories | 2 | 2010 | 110 | 0.090 |
Why?
| | Bacterial Proteins | 2 | 2012 | 981 | 0.090 |
Why?
| | Marsupialia | 1 | 1992 | 8 | 0.090 |
Why?
| | Cytosol | 2 | 2024 | 214 | 0.090 |
Why?
| | N-Formylmethionine Leucyl-Phenylalanine | 1 | 2012 | 38 | 0.090 |
Why?
| | Biomechanical Phenomena | 2 | 2015 | 852 | 0.090 |
Why?
| | DNA Fragmentation | 1 | 2012 | 39 | 0.090 |
Why?
| | Physicians | 1 | 2021 | 949 | 0.090 |
Why?
| | Chromosome Breakpoints | 1 | 2011 | 9 | 0.090 |
Why?
| | Time Factors | 2 | 2014 | 7140 | 0.090 |
Why?
| | Sperm Count | 1 | 2011 | 21 | 0.090 |
Why?
| | Founder Effect | 1 | 2011 | 13 | 0.090 |
Why?
| | Heat Shock Transcription Factors | 1 | 2011 | 21 | 0.090 |
Why?
| | France | 1 | 2011 | 40 | 0.090 |
Why?
| | Polymorphism, Genetic | 2 | 2005 | 613 | 0.090 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2012 | 28 | 0.090 |
Why?
| | Germ Cells | 1 | 2012 | 65 | 0.090 |
Why?
| | Microbiological Techniques | 1 | 2012 | 34 | 0.090 |
Why?
| | Plasmids | 2 | 2023 | 375 | 0.090 |
Why?
| | Telemedicine | 1 | 2021 | 957 | 0.090 |
Why?
| | Protease Inhibitors | 1 | 2012 | 101 | 0.090 |
Why?
| | Disorders of Sex Development | 1 | 1992 | 40 | 0.090 |
Why?
| | Metaphase | 1 | 2011 | 33 | 0.080 |
Why?
| | Rats | 5 | 2025 | 5570 | 0.080 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2012 | 104 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2024 | 2365 | 0.080 |
Why?
| | Interleukin-8 | 1 | 2012 | 269 | 0.080 |
Why?
| | Clinical Laboratory Techniques | 1 | 2011 | 96 | 0.080 |
Why?
| | Disease Notification | 1 | 2010 | 16 | 0.080 |
Why?
| | Comoros | 1 | 2010 | 1 | 0.080 |
Why?
| | Indian Ocean | 1 | 2010 | 1 | 0.080 |
Why?
| | Cultural Evolution | 1 | 2010 | 5 | 0.080 |
Why?
| | Africa, Eastern | 1 | 2010 | 12 | 0.080 |
Why?
| | Bioterrorism | 1 | 2010 | 31 | 0.080 |
Why?
| | Infant, Newborn | 1 | 2022 | 6399 | 0.080 |
Why?
| | Protein Transport | 1 | 2012 | 437 | 0.080 |
Why?
| | Extracellular Matrix | 1 | 2015 | 560 | 0.080 |
Why?
| | Genetic Markers | 4 | 2001 | 332 | 0.080 |
Why?
| | Haplotypes | 2 | 2009 | 495 | 0.080 |
Why?
| | Enzyme Activation | 3 | 2019 | 762 | 0.080 |
Why?
| | Genetic Association Studies | 1 | 2011 | 369 | 0.080 |
Why?
| | Arabs | 1 | 2009 | 10 | 0.080 |
Why?
| | Gene Flow | 1 | 2010 | 85 | 0.080 |
Why?
| | Alternative Splicing | 1 | 2012 | 247 | 0.080 |
Why?
| | Cohort Studies | 2 | 2010 | 5957 | 0.070 |
Why?
| | Mice, Inbred Strains | 3 | 2000 | 396 | 0.070 |
Why?
| | Viral Load | 1 | 2011 | 528 | 0.070 |
Why?
| | Washington | 1 | 2009 | 148 | 0.070 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2010 | 156 | 0.070 |
Why?
| | SUMO-1 Protein | 1 | 2008 | 18 | 0.070 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 978 | 0.070 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2025 | 925 | 0.070 |
Why?
| | Mice, Transgenic | 5 | 2016 | 2184 | 0.070 |
Why?
| | Sequence Alignment | 2 | 2011 | 371 | 0.070 |
Why?
| | Erythrocytes | 1 | 2014 | 750 | 0.070 |
Why?
| | Introns | 2 | 2000 | 255 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 2019 | 0.070 |
Why?
| | Heterochromatin | 1 | 2008 | 66 | 0.070 |
Why?
| | Factor IXa | 1 | 2007 | 16 | 0.070 |
Why?
| | Sequence Analysis, DNA | 1 | 2010 | 828 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1360 | 0.060 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2007 | 88 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 2 | 2007 | 2350 | 0.060 |
Why?
| | Disease Outbreaks | 1 | 2010 | 423 | 0.060 |
Why?
| | Cell Cycle Proteins | 2 | 2004 | 628 | 0.060 |
Why?
| | Molecular Weight | 1 | 2007 | 312 | 0.060 |
Why?
| | Cricetinae | 1 | 2007 | 296 | 0.060 |
Why?
| | Dimerization | 1 | 2007 | 190 | 0.060 |
Why?
| | Thromboplastin | 1 | 2007 | 64 | 0.060 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2007 | 76 | 0.060 |
Why?
| | Aged | 4 | 2017 | 25955 | 0.060 |
Why?
| | Sequence Homology, Amino Acid | 4 | 2001 | 393 | 0.060 |
Why?
| | Actin Cytoskeleton | 1 | 1987 | 103 | 0.060 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2007 | 374 | 0.060 |
Why?
| | Up-Regulation | 2 | 2023 | 848 | 0.060 |
Why?
| | Language | 1 | 2009 | 323 | 0.060 |
Why?
| | Seminal Plasma Proteins | 1 | 2006 | 11 | 0.060 |
Why?
| | Prognosis | 1 | 2015 | 4312 | 0.060 |
Why?
| | Pharmacokinetics | 1 | 2026 | 32 | 0.060 |
Why?
| | Cytoskeleton | 1 | 1987 | 197 | 0.060 |
Why?
| | Automation | 1 | 2025 | 104 | 0.060 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2025 | 32 | 0.060 |
Why?
| | Transition Temperature | 1 | 2025 | 28 | 0.060 |
Why?
| | Factor VII | 1 | 2005 | 24 | 0.060 |
Why?
| | Apolipoproteins E | 1 | 2025 | 93 | 0.060 |
Why?
| | Gene Conversion | 1 | 2004 | 7 | 0.050 |
Why?
| | Evolution, Molecular | 2 | 2000 | 518 | 0.050 |
Why?
| | Actins | 1 | 1987 | 421 | 0.050 |
Why?
| | Phosphatidylethanolamines | 1 | 2025 | 76 | 0.050 |
Why?
| | Wounds and Injuries | 1 | 2013 | 960 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2007 | 751 | 0.050 |
Why?
| | Chromosome Inversion | 1 | 2004 | 19 | 0.050 |
Why?
| | Blotting, Western | 1 | 2007 | 1161 | 0.050 |
Why?
| | Leukocyte Common Antigens | 1 | 2024 | 87 | 0.050 |
Why?
| | Cell Lineage | 1 | 2026 | 376 | 0.050 |
Why?
| | Biomarkers | 1 | 2015 | 4261 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2922 | 0.050 |
Why?
| | Chemokine CXCL12 | 1 | 2023 | 86 | 0.050 |
Why?
| | Germ-Line Mutation | 1 | 2004 | 176 | 0.050 |
Why?
| | Pandemics | 2 | 2022 | 1700 | 0.050 |
Why?
| | Fluorocarbons | 1 | 2024 | 119 | 0.050 |
Why?
| | Disease Resistance | 1 | 2023 | 29 | 0.050 |
Why?
| | Crops, Agricultural | 1 | 2023 | 31 | 0.050 |
Why?
| | Plant Diseases | 1 | 2023 | 44 | 0.050 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2023 | 129 | 0.050 |
Why?
| | Biological Factors | 1 | 2023 | 39 | 0.050 |
Why?
| | Immunity | 1 | 2023 | 139 | 0.050 |
Why?
| | Genetic Research | 1 | 2023 | 17 | 0.050 |
Why?
| | Extracellular Matrix Proteins | 1 | 2024 | 156 | 0.050 |
Why?
| | RNA Interference | 1 | 2024 | 473 | 0.050 |
Why?
| | Foreign-Body Reaction | 1 | 2023 | 36 | 0.050 |
Why?
| | Signal Transduction | 3 | 2026 | 5185 | 0.050 |
Why?
| | Sex Determination Analysis | 2 | 1992 | 9 | 0.050 |
Why?
| | Bacterial Infections | 2 | 2017 | 247 | 0.050 |
Why?
| | DNA, Complementary | 2 | 2000 | 273 | 0.050 |
Why?
| | Retroelements | 2 | 2001 | 51 | 0.040 |
Why?
| | Sperm Injections, Intracytoplasmic | 1 | 2002 | 10 | 0.040 |
Why?
| | Minor Histocompatibility Antigens | 2 | 2000 | 47 | 0.040 |
Why?
| | Toll-Like Receptor 4 | 1 | 2024 | 277 | 0.040 |
Why?
| | Genetic Testing | 2 | 2005 | 480 | 0.040 |
Why?
| | Chromosomes, Human | 2 | 1998 | 41 | 0.040 |
Why?
| | In Situ Nick-End Labeling | 2 | 2012 | 120 | 0.040 |
Why?
| | Young Adult | 3 | 2017 | 14122 | 0.040 |
Why?
| | Drug Liberation | 1 | 2021 | 35 | 0.040 |
Why?
| | Child | 5 | 2016 | 22600 | 0.040 |
Why?
| | Nanotechnology | 1 | 2022 | 121 | 0.040 |
Why?
| | DEAD-box RNA Helicases | 2 | 2000 | 89 | 0.040 |
Why?
| | Middle Aged | 4 | 2017 | 35971 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 88 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 242 | 0.040 |
Why?
| | Transforming Growth Factor beta | 1 | 2024 | 475 | 0.040 |
Why?
| | Antibodies, Neutralizing | 1 | 2024 | 341 | 0.040 |
Why?
| | Sequence Homology | 1 | 2000 | 44 | 0.040 |
Why?
| | Cloning, Molecular | 3 | 1998 | 535 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2008 | 2137 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2008 | 3603 | 0.040 |
Why?
| | Genes, MHC Class II | 1 | 2000 | 76 | 0.040 |
Why?
| | NF-kappa B | 1 | 2024 | 657 | 0.040 |
Why?
| | Protons | 1 | 2020 | 97 | 0.040 |
Why?
| | Wound Healing | 1 | 2023 | 352 | 0.040 |
Why?
| | Quartz Crystal Microbalance Techniques | 1 | 2019 | 7 | 0.040 |
Why?
| | Protein Conformation | 1 | 2023 | 935 | 0.040 |
Why?
| | Lupus Coagulation Inhibitor | 1 | 2019 | 6 | 0.040 |
Why?
| | Histocompatibility Antigens | 1 | 2000 | 102 | 0.040 |
Why?
| | Factor X | 1 | 2019 | 25 | 0.040 |
Why?
| | Stereoisomerism | 1 | 2019 | 102 | 0.040 |
Why?
| | Prothrombin Time | 1 | 2019 | 33 | 0.040 |
Why?
| | Half-Life | 1 | 2019 | 152 | 0.040 |
Why?
| | Mammals | 2 | 1998 | 296 | 0.040 |
Why?
| | Blood Platelets | 1 | 2023 | 379 | 0.040 |
Why?
| | Proteomics | 1 | 2026 | 1183 | 0.040 |
Why?
| | Bone Marrow Cells | 1 | 2020 | 321 | 0.040 |
Why?
| | Chromosome Aberrations | 1 | 2000 | 164 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2000 | 175 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2024 | 1207 | 0.040 |
Why?
| | Quality Control | 1 | 2019 | 164 | 0.040 |
Why?
| | Heart | 1 | 2023 | 626 | 0.040 |
Why?
| | Chromosomes, Bacterial | 1 | 1998 | 13 | 0.040 |
Why?
| | Dosage Compensation, Genetic | 1 | 1998 | 11 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 743 | 0.040 |
Why?
| | Microscopy, Confocal | 1 | 2019 | 317 | 0.040 |
Why?
| | Cysteine | 1 | 2019 | 207 | 0.030 |
Why?
| | Thrombin | 1 | 2019 | 167 | 0.030 |
Why?
| | Platypus | 1 | 1998 | 1 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2021 | 854 | 0.030 |
Why?
| | Sex Determination Processes | 1 | 1998 | 11 | 0.030 |
Why?
| | Gene Expression | 2 | 1994 | 1476 | 0.030 |
Why?
| | Biosensing Techniques | 1 | 2019 | 140 | 0.030 |
Why?
| | Specimen Handling | 1 | 2019 | 187 | 0.030 |
Why?
| | Thermodynamics | 1 | 2019 | 425 | 0.030 |
Why?
| | Hemorrhage | 1 | 2023 | 813 | 0.030 |
Why?
| | Tensile Strength | 1 | 2017 | 98 | 0.030 |
Why?
| | Primates | 1 | 1998 | 133 | 0.030 |
Why?
| | Controlled Before-After Studies | 1 | 2016 | 15 | 0.030 |
Why?
| | Bacterial Adhesion | 1 | 2017 | 110 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2009 | 8284 | 0.030 |
Why?
| | Muridae | 1 | 1996 | 6 | 0.030 |
Why?
| | Species Specificity | 1 | 1998 | 573 | 0.030 |
Why?
| | Genetic Loci | 2 | 2009 | 260 | 0.030 |
Why?
| | Drosophila | 1 | 1998 | 167 | 0.030 |
Why?
| | Chromatin Assembly and Disassembly | 1 | 2017 | 108 | 0.030 |
Why?
| | Ovalbumin | 1 | 2016 | 190 | 0.030 |
Why?
| | Vaccines, Synthetic | 1 | 2016 | 138 | 0.030 |
Why?
| | Spermatogonia | 1 | 2016 | 16 | 0.030 |
Why?
| | Animals, Outbred Strains | 1 | 2015 | 6 | 0.030 |
Why?
| | Haploidy | 1 | 2016 | 28 | 0.030 |
Why?
| | Materials Testing | 1 | 2017 | 348 | 0.030 |
Why?
| | Restriction Mapping | 2 | 1994 | 80 | 0.030 |
Why?
| | Oocytes | 1 | 2016 | 178 | 0.030 |
Why?
| | Cosmids | 1 | 1995 | 8 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1056 | 0.030 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2017 | 204 | 0.030 |
Why?
| | In Situ Hybridization | 2 | 1994 | 318 | 0.030 |
Why?
| | Patient Selection | 1 | 2019 | 727 | 0.030 |
Why?
| | Acrosome | 1 | 2014 | 6 | 0.030 |
Why?
| | Cell Shape | 1 | 2015 | 56 | 0.030 |
Why?
| | Family Health | 2 | 2007 | 191 | 0.030 |
Why?
| | Genes, Y-Linked | 1 | 2014 | 1 | 0.030 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2015 | 76 | 0.030 |
Why?
| | Fluorescence | 1 | 2015 | 153 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1742 | 0.030 |
Why?
| | Mice, Inbred CBA | 3 | 2000 | 57 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 174 | 0.030 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2015 | 203 | 0.030 |
Why?
| | Anticoagulants | 1 | 2019 | 729 | 0.030 |
Why?
| | Administration, Oral | 1 | 2016 | 851 | 0.030 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 1994 | 177 | 0.030 |
Why?
| | Emergency Medicine | 1 | 2016 | 263 | 0.020 |
Why?
| | Reproducibility of Results | 2 | 2012 | 3414 | 0.020 |
Why?
| | Adolescent | 3 | 2010 | 22409 | 0.020 |
Why?
| | Hominidae | 1 | 1994 | 87 | 0.020 |
Why?
| | Cadherins | 1 | 2015 | 200 | 0.020 |
Why?
| | Epitopes | 1 | 1995 | 479 | 0.020 |
Why?
| | Equipment Failure Analysis | 1 | 2013 | 124 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2014 | 396 | 0.020 |
Why?
| | Karyotyping | 2 | 2012 | 105 | 0.020 |
Why?
| | Tissue Engineering | 1 | 2017 | 441 | 0.020 |
Why?
| | Research Design | 1 | 2019 | 1129 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2009 | 17149 | 0.020 |
Why?
| | Family Practice | 1 | 2016 | 402 | 0.020 |
Why?
| | Sex Characteristics | 2 | 1995 | 776 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2020 | 1209 | 0.020 |
Why?
| | Cattle | 1 | 2015 | 975 | 0.020 |
Why?
| | Amsacrine | 1 | 1992 | 1 | 0.020 |
Why?
| | Chromosome Walking | 1 | 1992 | 1 | 0.020 |
Why?
| | DNA, Superhelical | 1 | 1992 | 12 | 0.020 |
Why?
| | Graft Rejection | 1 | 1995 | 512 | 0.020 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1991 | 63 | 0.020 |
Why?
| | Dinucleoside Phosphates | 1 | 1992 | 31 | 0.020 |
Why?
| | BK Virus | 1 | 2011 | 17 | 0.020 |
Why?
| | DNA Topoisomerases, Type II | 1 | 1992 | 47 | 0.020 |
Why?
| | Polymorphism, Single-Stranded Conformational | 2 | 2002 | 26 | 0.020 |
Why?
| | Antigens, CD | 1 | 2015 | 552 | 0.020 |
Why?
| | Equipment Design | 1 | 2013 | 527 | 0.020 |
Why?
| | Gene Library | 1 | 1992 | 123 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 1992 | 158 | 0.020 |
Why?
| | Caspases | 1 | 2012 | 229 | 0.020 |
Why?
| | Histological Techniques | 1 | 2011 | 39 | 0.020 |
Why?
| | Brucella abortus | 1 | 2010 | 4 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 339 | 0.020 |
Why?
| | United States Food and Drug Administration | 1 | 2012 | 205 | 0.020 |
Why?
| | Bacillus anthracis | 1 | 2010 | 13 | 0.020 |
Why?
| | Observer Variation | 1 | 2011 | 355 | 0.020 |
Why?
| | Cytomegalovirus | 1 | 2011 | 168 | 0.020 |
Why?
| | Herpesvirus 4, Human | 1 | 2011 | 176 | 0.020 |
Why?
| | Bacteria | 1 | 2017 | 894 | 0.020 |
Why?
| | Civil Defense | 1 | 2010 | 21 | 0.020 |
Why?
| | Pathology, Clinical | 1 | 2010 | 29 | 0.020 |
Why?
| | Pathology | 1 | 2010 | 21 | 0.020 |
Why?
| | Sentinel Surveillance | 1 | 2010 | 46 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2012 | 407 | 0.020 |
Why?
| | Health Planning | 1 | 2010 | 47 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 364 | 0.020 |
Why?
| | Models, Chemical | 1 | 1992 | 264 | 0.020 |
Why?
| | Francisella tularensis | 1 | 2010 | 33 | 0.020 |
Why?
| | Resource Allocation | 1 | 2010 | 52 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2015 | 894 | 0.020 |
Why?
| | Leukemia | 1 | 1992 | 245 | 0.020 |
Why?
| | Ovary | 1 | 2011 | 226 | 0.020 |
Why?
| | Geography | 1 | 2009 | 203 | 0.020 |
Why?
| | Microsatellite Repeats | 1 | 2009 | 155 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2010 | 537 | 0.020 |
Why?
| | Feces | 1 | 2012 | 513 | 0.020 |
Why?
| | Histone Demethylases | 2 | 2000 | 38 | 0.020 |
Why?
| | Pediatrics | 1 | 2016 | 1121 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1537 | 0.020 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2008 | 129 | 0.020 |
Why?
| | Cell-Free System | 1 | 1987 | 53 | 0.020 |
Why?
| | Neurotoxins | 1 | 1987 | 28 | 0.020 |
Why?
| | Monoamine Oxidase | 1 | 1987 | 27 | 0.020 |
Why?
| | Viscosity | 1 | 1987 | 92 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1995 | 0.020 |
Why?
| | Indicators and Reagents | 1 | 2007 | 106 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2014 | 2037 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 2007 | 186 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1928 | 0.020 |
Why?
| | X Chromosome Inactivation | 1 | 2006 | 25 | 0.010 |
Why?
| | XYY Karyotype | 1 | 2006 | 24 | 0.010 |
Why?
| | Public Health | 1 | 2010 | 569 | 0.010 |
Why?
| | Mice, Inbred C3H | 2 | 1996 | 252 | 0.010 |
Why?
| | Frameshift Mutation | 1 | 2004 | 30 | 0.010 |
Why?
| | Inheritance Patterns | 1 | 2004 | 44 | 0.010 |
Why?
| | Prospective Studies | 1 | 2016 | 7994 | 0.010 |
Why?
| | Mosaicism | 1 | 2004 | 73 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2016 | 6041 | 0.010 |
Why?
| | Disease Management | 1 | 2007 | 650 | 0.010 |
Why?
| | Lymphocytes | 1 | 2004 | 379 | 0.010 |
Why?
| | Mutagenesis, Insertional | 1 | 2002 | 68 | 0.010 |
Why?
| | RNA Splice Sites | 1 | 2002 | 52 | 0.010 |
Why?
| | Codon, Nonsense | 1 | 2002 | 44 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2006 | 1705 | 0.010 |
Why?
| | Fibroblasts | 1 | 1987 | 1019 | 0.010 |
Why?
| | Hybrid Cells | 1 | 2001 | 49 | 0.010 |
Why?
| | Blood Specimen Collection | 1 | 2001 | 37 | 0.010 |
Why?
| | Dogs | 1 | 2002 | 438 | 0.010 |
Why?
| | H-2 Antigens | 1 | 2000 | 111 | 0.010 |
Why?
| | RNA Splicing | 1 | 2001 | 286 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2001 | 333 | 0.010 |
Why?
| | Chromosomes, Human, Pair 12 | 1 | 1998 | 21 | 0.010 |
Why?
| | Isoantibodies | 1 | 1999 | 57 | 0.010 |
Why?
| | Blotting, Northern | 1 | 1998 | 203 | 0.010 |
Why?
| | Child, Preschool | 3 | 2005 | 11790 | 0.010 |
Why?
| | Cost-Benefit Analysis | 1 | 2001 | 638 | 0.010 |
Why?
| | Infant | 2 | 2004 | 10023 | 0.010 |
Why?
| | Oxidoreductases, N-Demethylating | 1 | 1996 | 17 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 1996 | 124 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 1998 | 1251 | 0.010 |
Why?
| | Chromosomes, Artificial, Yeast | 1 | 1994 | 5 | 0.010 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1994 | 35 | 0.010 |
Why?
| | Crossing Over, Genetic | 1 | 1992 | 7 | 0.010 |
Why?
| | Aneuploidy | 1 | 1973 | 90 | 0.010 |
Why?
| | DNA Topoisomerases, Type I | 1 | 1992 | 16 | 0.010 |
Why?
| | Tumor Stem Cell Assay | 1 | 1992 | 34 | 0.010 |
Why?
| | Deoxyribonucleotides | 1 | 1991 | 20 | 0.010 |
Why?
| | Carbamates | 1 | 1992 | 51 | 0.010 |
Why?
| | Vertebrates | 1 | 1991 | 67 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 1992 | 881 | 0.000 |
Why?
| | Sulfonamides | 1 | 1992 | 579 | 0.000 |
Why?
| | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 1987 | 4 | 0.000 |
Why?
| | Pargyline | 1 | 1987 | 3 | 0.000 |
Why?
| | Computer Simulation | 1 | 1992 | 1021 | 0.000 |
Why?
| | Risk Factors | 1 | 2001 | 10796 | 0.000 |
Why?
| | Cerebrovascular Circulation | 1 | 1987 | 289 | 0.000 |
Why?
| | Kinetics | 1 | 1987 | 1602 | 0.000 |
Why?
| | Dermatoglyphics | 1 | 1973 | 2 | 0.000 |
Why?
| | Mouth Mucosa | 1 | 1973 | 87 | 0.000 |
Why?
| | Intelligence | 1 | 1973 | 110 | 0.000 |
Why?
| | Myopia | 1 | 1973 | 59 | 0.000 |
Why?
| | Personality Disorders | 1 | 1973 | 78 | 0.000 |
Why?
| | Syndrome | 1 | 1973 | 379 | 0.000 |
Why?
| | Body Height | 1 | 1973 | 199 | 0.000 |
Why?
|
|
Mitchell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|